T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$2.57B |
| 2 |
GE Aerospace
GE
|
+$1.8B |
| 3 |
UnitedHealth
UNH
|
+$1.63B |
| 4 |
Marriott International
MAR
|
+$1.62B |
| 5 |
Apple
AAPL
|
+$1.3B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.87B |
| 2 |
JPMorgan Chase
JPM
|
+$1.64B |
| 3 |
Nike
NKE
|
+$1.59B |
| 4 |
Becton Dickinson
BDX
|
+$1.46B |
| 5 |
Alibaba
BABA
|
+$1.32B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.97% |
| 2 | Healthcare | 18.52% |
| 3 | Consumer Discretionary | 13.26% |
| 4 | Financials | 12.08% |
| 5 | Communication Services | 10.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABMD
1001
DELISTED
Abiomed Inc
ABMD
| $24.6M | ﹤0.01% |
169,138
-718,153
| -81% | -$119M |
|
1002
Patrick Industries
PATK
$2.78B
| $24.5M | ﹤0.01% |
1,306,980
+19,834
| +2% | +$632K |
|
1003
Aaon
AAON
$7.23B
| $24.4M | ﹤0.01% |
758,631
+1,107
| +0.1% | +$38.6K |
|
|
CTRA
1004
DELISTED
Coterra Energy
CTRA
| $24.2M | ﹤0.01% |
1,408,012
-130,572
| -8% | -$2.07M |
|
1005
Waters Corp
WAT
$40.6B
| $24.2M | ﹤0.01% |
132,783
+9,968
| +8% | +$2.1M |
|
1006
United Therapeutics
UTHR
$21.5B
| $24.2M | ﹤0.01% |
254,831
+208,234
| +447% | +$19.8M |
|
1007
EverQuote
EVER
$864M
| $24.1M | ﹤0.01% |
919,564
+13,071
| +1% | +$460K |
|
1008
Agnico Eagle Mines
AEM
$91.3B
| $24.1M | ﹤0.01% |
611,145
+64,917
| +12% | +$3.42M |
|
1009
DaVita
DVA
$11.4B
| $24.1M | ﹤0.01% |
316,882
+6,508
| +2% | +$512K |
|
1010
Dover
DOV
$27.8B
| $24M | ﹤0.01% |
286,366
-616,312
| -68% | -$65.3M |
|
1011
PENN Entertainment
PENN
$2.53B
| $24M | ﹤0.01% |
1,900,038
-410,269
| -18% | -$10.3M |
|
|
ADVM
1012
DELISTED
Adverum Biotechnologies
ADVM
| $24M | ﹤0.01% |
245,337
+120,158
| +96% | +$14M |
|
1013
Lennar Class A
LEN
$21.1B
| $23.9M | ﹤0.01% |
645,286
+37,216
| +6% | +$2.11M |
|
1014
GoDaddy
GDDY
$12.7B
| $23.7M | ﹤0.01% |
415,290
+4,821
| +1% | +$319K |
|
1015
Cincinnati Financial
CINF
$26.5B
| $23.7M | ﹤0.01% |
313,995
+23,845
| +8% | +$2.38M |
|
|
MODV
1016
DELISTED
ModivCare
MODV
| $23.5M | ﹤0.01% |
427,547
+406,409
| +1,923% | +$25.1M |
|
1017
Healthpeak Properties
DOC
$14.3B
| $23.4M | ﹤0.01% |
981,608
+79,081
| +9% | +$2.58M |
|
1018
Jack Henry & Associates
JKHY
$11.1B
| $23.3M | ﹤0.01% |
150,076
+11,336
| +8% | +$1.76M |
|
1019
Ligand Pharmaceuticals
LGND
$5.76B
| $23.3M | ﹤0.01% |
513,476
-19,321
| -4% | -$1.1M |
|
|
KDMN
1020
DELISTED
Kadmon Holdings, Inc.
KDMN
| $23.2M | ﹤0.01% |
5,527,706
+703,130
| +15% | +$3.03M |
|
1021
D.R. Horton
DHI
$41.9B
| $23.1M | ﹤0.01% |
679,133
+52,737
| +8% | +$2.74M |
|
|
TECD
1022
DELISTED
Tech Data Corp
TECD
| $23M | ﹤0.01% |
175,886
-8,763
| -5% | -$1.21M |
|
|
ITCI
1023
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $23M | ﹤0.01% |
1,494,485
+201,249
| +16% | +$4.37M |
|
1024
Seagate
STX
$209B
| $22.8M | ﹤0.01% |
467,820
+32,923
| +8% | +$1.76M |
|
1025
International Flavors & Fragrances
IFF
$21.4B
| $22.7M | ﹤0.01% |
222,233
-179,096
| -45% | -$22.3M |
|
Similar funds
T. Rowe Price Associates's Q1 2020 Portfolio in Review
As of Q1 2020, T. Rowe Price Associates held 2,612 positions worth $632B, down 18% from $771B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2020 filing shows 87 new, 1,525 increased, 823 reduced and 103 closed positions. Its largest new stake was Philips: 33,363,001 shares worth $1.07B. The largest sale was Boeing, an estimated $2.87B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2020 buy was Philips: 33,363,001 shares worth $1.07B.
- T. Rowe Price Associates added most to Humana in Q1 2020, an estimated $2.57B increase.
- T. Rowe Price Associates's biggest Q1 2020 reduction was Boeing, cutting an estimated $2.87B.
- T. Rowe Price Associates fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $846M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $632B portfolio in Q1 2020.
- T. Rowe Price Associates opened 87 new positions and closed 103 in Q1 2020.
- T. Rowe Price Associates's portfolio value fell 18% quarter-over-quarter to $632B.
Based on T. Rowe Price Associates's 13F filing for Q1 2020, filed 15 May 2020.